Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine in Urothelial Cancer and Solid Tumors
NCT05279690Phase 1Completed
- Sponsor
- Icahn School of Medicine at Mount Sinai
- Start
- Feb 2022
- Primary completion
- Dec 2024
- Modality
- Nucleic Acid-Directed Small Molecules, Classical Binding Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label trial of colchicine in urothelial carcinoma (UC) and solid tumor (3 cohorts), sponsored by Icahn School of Medicine at Mount Sinai. Primary endpoint: Percent Change in Peripheral blood CRP level at 28 days. Started Feb 2022; status: completed.
02
Drugs
colchicine
03
Conditions
urothelial carcinoma (UC)solid tumor
Beyond the preview
Go deeper on NCT05279690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05279690.